by Clinical Neuropsychologist Online | Wednesday, October 28, 2026 | Dementia
Abstract INTRODUCTION Plasma β-synuclein is a promising blood-based synaptic biomarker, but relationships with synaptic density as indicated by [11C]UCB-J positron emission tomography (PET), and blood biomarkers of Alzheimer’s disease (AD) pathology,...
by Clinical Neuropsychologist Online | Wednesday, October 28, 2026 | Dementia
Abstract BACKGROUND Although lecanemab has demonstrated clinical efficacy in early Alzheimer’s disease (AD), its cost-effectiveness in China remains uncertain. This study evaluated the long-term cost-effectiveness of lecanemab in Chinese patients from a societal...
by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Neuropsychology (general)
Journal of Neuropsychology, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | October 27, 2026 Neuro-General Previous...
by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Paediatric Neuropsychology
. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: | October 27, 2026 Neuro-Paediatric Previous Page
by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Dementia
Abstract BACKGROUND Genome-wide association studies (GWASs) identified multiple genetic variants associated with Alzheimer’s disease (AD) risk, yet the biological pathways linking these to amyloid and tau pathology remain unclear. METHODS We conducted a...